9I果冻制作厂官网

目录产物 » HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human
Manual
SDS
COAs

HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
￥9900
Z06610-100

产物介绍
Species Human
Protein Construction
HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer[Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and IVCPICSQK peptide]
Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&IVCPICSQK		 His Avi
N-term C-term
Purity >?95%?as?determined?by?Bis?Tris?PAGE?
>?95%?as?determined?by?HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
Synonyms HPV16; E7; MHC
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.